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Gene regulation by DNA binding small molecules could have impor-
tant therapeutic applications. This study reports the investigation
of a DNA-binding pyrrole-imidazole polyamide targeted to bind
the DNA sequence 5′-WGGWWW-3′ with reference to its potency
in a subcutaneous xenograft tumor model. The molecule is capable
of trafficking to the tumor site following subcutaneous injection
and modulates transcription of select genes in vivo. An FITC-la-
beled analogue of this polyamide can be detected in tumor-derived
cells by confocal microscopy. RNA deep sequencing (RNA-seq) of
tumor tissue allowed the identification of further affected genes,
a representative panel of which was interrogated by quantitative
reverse transcription-PCR and correlated with cell culture expres-
sion levels.
tumor RNA-sequencing ∣ eXpress ∣ in vivo circulation ∣ efficacy
Pyrrole-imidazole (Py-Im) polyamides represent a class ofmodular DNA minor groove binders with affinity and speci-
ficity comparable to the values observed with typical DNA bind-
ing proteins (1, 2). Our previous investigations have established a
framework for molecular recognition of the minor groove of
DNA by polyamides that can target predetermined DNA binding
sites (3–5). Cell culture experiments have shown that cellular up-
take of Py-Im polyamides targeting six-base pair sequences can be
observed (6). Subsequent studies demonstrated that Py-Im poly-
amides could antagonize DNA binding of transcription factors in
live cells. Interrogated transcription factors include the androgen
receptor (AR) (7), hypoxia inducible factor 1 alpha (HIF-1α) (8),
the glucocorticoid receptor (GR) (9), and nuclear factor kappa B
(NF-κB) (10).
Although there is more knowledge to be gained from deeper
genome-wide cell culture studies, the next frontier for Py-Im
polyamides as medicinally relevant small molecules lies in in vivo
applications. Our recent studies demonstrated that the pharma-
cokinetics and toxicity of Py-Im polyamides in mice depend on
architecture (11). Micromolar levels of compounds were observed
in mouse plasma for up to 48 h following either intraperitoneal
(i.p.) or subcutaneous (s.c.) injection. Efforts of Nagashima et al.
established that Py-Im polyamides of different architecture were
detectable in rat serum several hours after intravenous (i.v.)
administration (12). Matsuda et al. further showed that a Py-Im
polyamide targeted to the TGF-β1 promoter affected target gene
expression in vivo (rat renal cortex) without evidence of systemic
toxicity (13, 14). The present study focuses on the question of
whether Py-Im polyamides affect gene expression in vivo, speci-
fically in a xenograft model environment, employing a luciferase-
expressing derivative of the commonly used lung nonsmall cell
carcinoma line A549.
Results
Acetylated Py-Im Polyamide 1 is More Potent in Cell Culture Than the
Analog 2. The first set of experiments compared the in vitro gene
regulation activity of Py-Im polyamides 1 and 2, both targeted to
bind to the sequence 5′-WGGWWW-3′ (Fig. 1A). Our previous
efforts established that the polyamide 2 was capable of modulat-
ing a subset of TNF-inducible genes (10). Among the strongly
affected genes we had identified CCL2 and SERPINE1 as highly
repressed targets of 2.
The basal expression levels of CCL2 and SERPINE1 were suf-
ficiently high to enable the study of polyamide effects in the un-
induced state. We found that both 1 and 2 reduced the levels of
the two transcripts, but the effects exerted by 1 were substantially
more pronounced (Fig. 1B). In line with the previous study, pro-
longed incubation times resulted in stronger down-regulation of
the target genes—up to fivefold withCCL2 and 14-fold with SER-
PINE1. Furthermore, 1 was significantly more cytotoxic in vitro
than 2 against the chosen cell line with IC50 values of 13 5 μM
and 33 2 μM, respectively (SI Text, Fig. S1A). The more potent
Py-Im polyamide 1 was, therefore, chosen for in vivo gene reg-
ulation experiments. Cellular uptake measurements clearly
showed that the FITC-labeled analogue 3 was readily taken up
by A549-luc-C8 cells, resulting in characteristic nuclear fluores-
cence (SI Text, Fig. S1B).
Py-Im Polyamides 1 and 2 Reach Comparable Plasma Levels with Simi-
lar Circulation Times Following S.C. Injection. Prior to conducting in
vivo tumor xenograft experiments the pharmacokinetic profiles
of 1 and 2 were compared. Our previous investigations showed
that 2 could circulate in wild-type mice for several hours at mi-
cromolar plasma concentrations but dropped below the limit of
detection after 24 h (11). The compound was administered by
either the s.c. or the i.p. route and blood collected retro-orbitally.
The circulation experiment was conducted for the Py-Im polya-
mide 1 using subcutaneous administration conditions analogous
to those previously reported for 2. The observed plasma levels
compared well with those reported for 2 (Fig. 2 and Fig. S2).
Maximum plasma concentrations of 10 μM were attained for
both compounds 3 h post injection. The plasma elimination phase
appeared slightly shallower for the acetylated Py-Im polyamide 1
than for its close analog 2, but neither was detectable 24 h post
injection.
FITC-Labeled Py-Im Polyamide 3 Can Be Detected in Xenograft-Derived
Cell Nuclei. We proceeded to synthesize the fluorescent tagged
derivative of 1, Py-Im polyamide 3 (see SI Text, Fig. S1 for struc-
ture). Previous experiments had shown that a closely related
compound was stable in vivo and circulated in mice for several
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hours (15). The resultant mouse plasma was found to contain
the compound at micromolar concentrations and could be used
to produce characteristic nuclear staining of A549 cells in cul-
ture (15).
Immunocompromised mice (SCID-beige) were grafted subcu-
taneously (in the flank) with the commercially available A549-de-
rived luciferase expressing cell line A549-luc-C8 (see Materials
and Methods for details). In order to ensure that the Py-Im poly-
amide 3 was entering the tumors through the vascular system, the
animals were injected with the polyamide from a site distal to the
site of implantation. A representative experiment is depicted in
Fig. 3A. The tumor-derived cells from the treated animals were
found to display strong and characteristic nuclear staining, closely
resembling those in the cell culture experiments. Tumors from
vehicle-treated mice were prepared and found to be devoid of
nuclear fluorescence. This finding provided the impetus to per-
form treatment of xenografted animals with 1 and investigate
whether polyamide treatment could result in gene expression
changes of CCL2 and SERPINE1 in vivo.
Py-Im Polyamide 1 Represses CCL2 and SERPINE1 Transcription in Vivo.
We followed up by testing the potency of 1 to repress CCL2 and
SERPINE1 in the tumor xenograft setting. To ensure primer
selectivity towards human target genes, we isolated total RNA
from mouse spleens obtained from the SCID-beige strain and
conducted control quantitative reverse transcription-PCR (qRT-
PCR) experiments. None of the primers employed in this study
exhibited any substantial amplification of mouse RNA.
All experiments were performed in accord with the treatment
schedule displayed in Table S1 (SI Text) and following the general
humane endpoints criteria (see Materials and Methods). Mild an-
imal toxicity was observed with an overall weight loss not exceed-
ing 10% as a result of treatment. The transcript levels of CCL2
and SERPINE1 were reduced by a factor of 2.3 and 2.0, respec-
tively, by 1 (Fig. 3B). Gene expression changes were the same
whether normalized toGUSB or PPIA as the housekeeping gene.
Because the IC50 of Py-Im polyamide 1 against growth of A549-
luc-C8 was 13 5 μM and plasma levels of the compound up to
Fig. 1. (A) Hairpin Py-Im polyamides 1 and 2. (B) In vitro qRT-PCR (A549-luc-
C8 cell culture). Cells were incubated with 10 μM final 1 or 2 for 48 h or 72 h,
where indicated. All treatments were conducted with 0.1% DMSO as vehicle.
Fig. 2. Plasma values of 1 and 2 as obtained from analytical HPLC traces
(C57Bl/6 wild-type mice, four animals per data point, all injections were done
subcutaneously at 120 nmol∕animal). The levels were normalized to the in-
ternal reference 4 (Fig. S2). Datapoints shown for Py-Im polyamide 2 have
been previously reported (11).
Fig. 3. (A) FITC-labeled Py-Im polyamide 3 localizes to engrafted A549-luc-
C8 cells (SCID-beige mice). (B) qRT-PCR of tumor samples showing repression
of CCL2 and SERPINE1. Three independent experiments with N ¼ 5 animals
per treatment condition (vehicle vs 1) were averaged.
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10 μM were attainable for several hours post injection, it was
conceivable that 1 could affect tumor growth. Tumor size was
therefore assessed by luciferase imaging as outlined in Materials
and Methods. A linear correlation between tumor size and photon
number over several orders of magnitude has been previously
demonstrated for the cell line used (www.caliperls.com/assets/
018/7635.pdf). The luciferase output remained within experimen-
tal error between the two groups, suggesting that the gene expres-
sion changes did not stem from cytotoxicity (SI Text, Fig. S3).
Genome-Wide Effects of the Py-Im Polyamide 1. In order to establish
the global effects of 1 in a xenograft setting, we measured changes
in gene expression using RNA-seq in tumors from treated and
untreated mice (see Materials and Methods for details). As our
RNA-seq libraries contained a mixture of human and mouse
RNA derived from the xenograft as well as the host cells infiltrat-
ing it, we faced the challenge of accurately determining the tran-
scripts and genes fromwhich sequencing reads originate (Table S2
and discussion in the SI Text). We therefore designed an analysis
pipeline based upon mapping reads to a combined human and
mouse transcriptome and using the recently developed eXpress
software package (bio.math.berkeley.edu/eXpress/index.html) to
quantify probabilistically transcript abundance for both species
simultaneously (Fig. 4). The eXpress output was used as input
for differential expression analysis using DESeq (16).
Out of 22,092 genes, 618 (2.8%) experienced a statistically sig-
nificant change in expression at a confidence level of p < 0.05.
Within this subpopulation, 115 (0.52%) genes were repressed
at least twofold, whereas 53 genes (0.24%) showed at least a two-
fold up-regulation. For quality control purposes, one replicate was
resequenced using paired-end read sequencing with the read
length set at 100 nt. High correlation coefficients were determined
between the effective counts obtained by single- and paired-end
read sequencing, withR2 values of 0.97 and 0.94 for vehicle and 1,
respectively (see SI Text, Fig. S4 for correlation plots).
Comparison of RNA-seq and qRT-PCR for a Panel of Selected Genes in
Vivo. A representative panel of genes studied by RNA-seq was
further interrogated by qRT-PCR (Fig. 5, Upper and Table 1).
In addition to CCL2 and SERPINE1 that were discussed above,
we investigated the effects of 1 on transcription of NPTX1,
ROBO1, ATM, EGFR, and MMP28. The genes were selected
so as to range from strongly repressed (NPTX1) through weakly
down-regulated (ATM and EGFR) to up-regulated upon polya-
mide treatment (MMP28). NPTX1 experienced a 3.3-fold repres-
sion upon treatment with 1, whereas the expression of ATM was
reduced only 1.5-fold. The expression changes in EGFR detected
by qPCR lie close to the error of the experiment (1.2-fold down).
The expression of MMP28 on the other hand was up-regulated
1.5-fold upon treatment with the Py-Im polyamide 1. The genes
CCL2, NPTX1, SERPINE1, andMMP28 were categorized as dif-
ferentially expressed by both techniques (Table 1). Changes in ex-
pression of ATM and ROBO1 were only statistically significant
assessed by qRT-PCR, not by RNA-seq (p-values over 0.05)
Comparison of in Vivo and in Vitro Effects of 1 by qRT-PCR on a Panel
of Selected Genes. The gene expression changes in the in vivo
xenograft setting were compared to those observed in cell culture
(Fig. 5, Lower and Table S3). Prolonged incubation with Py-Im
polyamide 1 in cell culture generally led to more pronounced ef-
fects (48 h vs 72 h), the only exception being MMP28, for which
no effect was observed in cell culture regardless of the incubation
time. The correspondence between the in vivo experiment and
the cell culture control was found to depend strongly on the tran-
script interrogated. The in vitro effect of 1 on NPTX1 expression
at 72 h incubation was very close to that observed in vivo (3.5-fold
vs 3.3-fold), whereas for CCL2 the gene repression in xenografts
resembled more closely the 48 h incubation time point from cell
culture experiments (2.3-fold vs 2.2-fold). While MMP28 expres-
sion was unchanged in cell culture, all other interrogated genes
were affected more strongly than in the xenograft setting. The
largest difference was noted for SERPINE1, which was repressed
2.0-fold in vivo but experienced a down-regulation in cell culture
amounting to as much as 15.7-fold.
Discussion
The present study shows that the polyamide 1 is capable of traf-
ficking to a xenografted tumor and yielding measurable gene
expression changes. Following the establishment of pharmacoki-
netic properties of Py-Im polyamides targeted to the sequence 5′-
WGGWWW-3′ (11), this is the next important step towards the
application of Py-Im polyamides in a setting relevant to disease.
Comparison Between Xenografts and Cell Culture. Quantitative
correlation between the two settings is of high interest, but dif-
ferences in exposure times and concentrations of the Py-Im poly-
amide 1 between cell culture and at the tumor site need to be kept
in mind. Typical exposure times in cell culture range from 48 h to
72 h whereas final treatment concentrations do not exceed 10 μM
(10). Most of the polyamide remains in the medium so that the
concentration is effectively invariant over the experimental time-
course. One fundamental difference in the in vivo experiment is
that the serum concentration of 1 does change as a function of
postinjection time. Whereas a concentration maximum of ap-
proximately 10 μM is typically attained under chosen administra-
tion conditions, the circulating levels of 1 drop below the level of
detection (high nanomolar) 24 h postinjection. This results in os-
cillatory compound levels over the course of the 10 d experiment
(Fig. 2 and Table S1). Another difference is the inherent hetero-
geneity of cancerous tissue. Some subpopulations of xenografted
cells lie in closer proximity to newly formed blood vessels and
hence may be more readily accessible to the drug than others
(17, 18). Interactions with the host may also lead to additional
complexity (19).
Comparison of the three genes that were most strongly af-
fected in the in vivo experiment to their behavior in cell culture
is of interest. Among the genes that were examined by qRT-PCR,
NPTX1 experienced the strongest in vivo repression (3.3-fold
down). This was similar to the effects observed in cell culture,
namely 2.6-fold and 3.5-fold repression at 48 h and 72 h, respec-
tively. The effect of the Py-Im polyamide 1 against cells in culture
was rather similar for both exposure times tested. By contrast,
SERPINE1 was less strongly affected in vivo compared to in vitro.
While the in vivo repression amounted to 2.0-fold, the down-reg-
ulation was substantially more pronounced in cell culture. Tran-
scription was reduced 8.3-fold after 48 h incubation and 15.7-fold
after 72 h. Expression of CCL2 was down-regulated 2.3-fold in
the xenograft experiment whereas the cell culture repression was
2.2-fold (48 h) and 4.4-fold (72 h). This comparative analysis
prompts a note of caution, for it is evident that there can be sig-
nificant variability between gene expression changes observed in
vitro and in vivo. We conclude, however, that cell culture data can
be used to support in vivo findings in most cases.
Fig. 4. Schematic representation of the pipeline for RNA-seq analysis of tu-
mor-derived RNA. Three independent experiments for each of which N ¼ 5
animals per treatment condition (vehicle vs 1) were averaged, were jointly
analyzed.
















Tumor RNA-seq.Because of tumor heterogeneity, stemming mostly
from host-derived tumor infiltrating cells, the fraction of sequen-
cing reads unambiguously originating from the human transcrip-
tome was at most only 60%, the rest being mouse-derived (see
SI Text, Table S2). The computational pipeline described here
solves this problem by applying simultaneous probabilistic map-
ping to both the human and the mouse transcriptome. Moreover,
we have confirmed the viability of this approach by conducting
qRT-PCR on a representative panel of genes, showing good
correlation between the two methods (Table 1) and we expect
it to be widely useful to researchers conducting similar types of
experiments in different settings. Genome-wide analysis showed a
total of 168 genes to be affected by the Py-Im polyamide 1 in
xenografts, which corresponds to 0.76% of the NCBI reference
sequence (refSeq) annotation (p < 0.05, at least twofold change).
For comparison, Matsuda et al. reported gene expression changes
in rat kidney cortex for 3% of genes interrogated by microar-
ray (14).
Effects on Tumor Size.The tumor sizes were the same (within error)
between the animal groups that received repeated injections of
Py-Im polyamide 1 and vehicle (Fig. S3). The absence of any
significant effect on tumor size could be due to a variety of fac-
tors. The compound might not reach sufficient average levels in
the tumor. The IC50 value of 1 is 13 5 μM (Sulforhodamine B
assay, 72 h incubation, 24 h recovery; see also SI Text, Fig. S1A).
Although micromolar levels of 1 can be maintained for several
hours postinjection, the overall exposure to the compound may
still be too low to produce any measurable effect on size. Treat-
ment efficiency could be enhanced by using more potent Py-Im
polyamides or changing the route of administration, e.g., by em-
ploying osmotic pumps to maintain steady compound levels over
the course of the experiment (20). Alternatively, Py-Im polya-
mide 1may not penetrate the tumor to a sufficient depth because
of tissue inhomogeneity. Tissue penetration rates can depend on
compound lipophilicity and flexibility. Py-Im polyamide substitu-
ent variation affords a means to alter binding site preference,
affinity, specificity, lipophilicity, and cellular uptake rates (21).
Finally, the treatment schedule may be too short. Initial tumor
growth is rather slow, the A549-luc-C8 tumors typically entering
the exponential growth phase only several weeks after grafting
(www.caliperls.com/assets/018/7635.pdf).
Conclusions
This study reports the ability of Py-Im polyamide 1 and its fluor-
escent labeled analogue 3 to traffic to the subcutaneously grafted
A549-luc-C8 tumor. Unambiguous nuclear staining of tumor-
derived cells with the FITC-analogue 3 evidenced the ability of
the compound to remain at the site several days after injection.
The nonfluorescent parent Py-Im polyamide 1 was capable of
affecting gene expression in the tumor, and most trends corre-
lated satisfactorily with cell culture data. From the panel of genes
examined by qRT-PCR, the strongest effect was measured for
NPTX1, which was repressed 3.3-fold.MMP28 on the other hand
experienced a small but significant induction of 1.5-fold upon
treatment. It is of the highest importance to increase the potency
of a compound at the tumor site, while minimizing its toxic effects
to the host. Strategies to that end include testing of Py-Im poly-
amides targeted to different sequences, incorporating further
modifications, development of formulations that would enhance
selectivity of delivery and testing of alternative treatment
schedules.
Fig. 5. A panel of genes affected by 1 in an A549-luc-C8 xenograft in SCID-bg animals (Upper) and cell culture (Lower). Xenograft: three independent
experiments with N ¼ 5 animals per treatment condition (vehicle vs 1) were averaged. Cell culture: where indicated, the cells were incubated with Py-Im
polyamide 1 at 10 μM final concentration in 0.1% DMSO as vehicle.
Table 1. Comparison of qRT-PCR and RNA-seq of A549-luc-C8
tumor xenograft gene expression levels normalized to GUSB
as the housekeeping gene (qRT-PCR). Brackets indicate gene
upregulation upon treatment. Three independent
experiments with N ¼ 5 animals per treatment condition
(vehicle vs 1) were averaged. RNA-seq was performed with
single-end reads of 50 nt length. See SI Text for annotation of
these gene products
Gene Fold change (qPCR) Fold change (RNA-seq)
ATM 1.5 ± 0.2 1.5 (p > 0.05)
NPTX1 3.3 ± 0.6 2.9 (p < 0.001)
ROBO1 1.5 ± 0.2 1.7 (p > 0.05)
MMP28 [1.5 ± 0.3] [2.0] (p < 0.05)
EGFR 1.2 ± 0.2 1.3 (p > 0.05)
CCL2 2.3 ± 0.4 1.7 (p < 0.001)
SERPINE1 2.0 ± 0.2 1.8 (p < 0.001)
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Materials and Methods
Polyamide Synthesis and Characterization. The polyamides 1–3 were synthe-
sized following modified solid phase synthesis protocols (22). Typically, yields
between 25 and 40% were observed. Compound purities were confirmed
by analytical HPLC. Compounds 1 and 3 were characterized by MALDI-TOF
MS as singly protonated species. Following masses were determined: 1 cal-
culated for C67H79N22O13 ½Mþ Hþ 1,399.6, found 1,399.5; 3 calculated for
C80H86N23O15S ½Mþ Hþ 1,640.6, found 1,642.3. Analytical data for 2 were
in agreement with what has been previously reported (10).
In Vitro Cell Culture Experiments. All experiments were conducted with A549-
luc-C8 cells, unless specifically mentioned otherwise. Cells were grown in
RPMI medium 1640, which was supplemented with 10% FBS and 1% peni-
cillin/streptomycin, and did not exceed 25 passages. Confocal imaging, cellu-
lar proliferation and viability experiments as well as gene expression analyses
by quantitative RT-PCR were performed following our previously published
protocols (7, 10, 21, 23). Gene expression was normalized against GUSB as
housekeeping gene. All primers yielded single amplicons as determined by
both melting denaturation analysis and agarose gel electrophoresis. The fol-
lowing primer pairs were used. CCL2: fwd 5′-AGT GTC CCA AAG AAG CTG
TGA-3′ rev. 5′-AAT CCT GAA CCC ACT TCT GCT-3′; SERPINE1: fwd. 5′-AGA
ACA GGA GGA GAA ACC CA-3′ rev. 5′-AGC TCC TTG TAC AGA TGC CG-3′
GUSB: fwd. 5′-CTC ATT TGG AAT TTT GCC GAT T-3′ rev. 5′-CCC AGT GAA
GAT CCC CTT TTT A-3′. ATM: fwd. 5′-GCT GTG AGA AAA CCA TGG AA-3′
rev. 5′-TTC AAA GGA TTC ATG GTC CAG-3′; EGFR: fwd. 5′-GGG CTC TGG
AGG AAA AGA AA-3′ rev. 5′-TCC TCT GGA GGC TGA GAA AA-3′; MMP28:
fwd. 5′-CCT GCA GCT GCT ACT GTG G-3′ rev. 5′-CTT TGG GGA CCT GTT
CAT TG-3′; NPTX1: fwd. 5′-ACC GAG GAG AGG GTC AAG AT-3′ rev. 5′-GTG
GGA ATG TGA GCT GGA AC-3′; ROBO1: fwd. 5′-CAA TGC ATC GCT GGA
AGT AG-3′ rev. 5′-TTC TTC CAT GAA ATG GTG GG-3′.
Mouse Experiments. Pharmacokinetics. Analyses for Py-Im polyamide 1 were
conducted following our recently established protocols (11). Briefly, the
compound was injected subcutaneously into C57/Bl6 mice as a PBS∕DMSO
solution (4∶1, 200 μL per injection, four animals per group). Blood was col-
lected retro-orbitally at the indicated time points. Plasma was obtained by
centrifugation, precleared from protein by methanol precipitation and com-
pound levels determined by analytical HPLC. The plasma levels obtainedwere
compared with those previously reported for 2. Xenografts. Grafting with
A549-luc-C8. Experiments were performed in female SCID-beige mice
(Charles River) between 8 and 12 wk of age. Cells were injected into the left
flank area of the animals as suspensions of 25 × 106 mL−1 in RPMI, 200 μL per
injection. Treatment and tumor proliferation monitoring. Mice were treated
following the schedule delineated in SI Text (Table S1). Tumor proliferation
was monitored using the XENOGEN imaging device. The animals were
anesthetized with 2–5% isoflurane and subsequently transferred to the ima-
ging chamber, whereupon the isoflurane levels were reduced to 1–2.5%. The
floor of the imager was heated to þ37 °C to avoid hypothermia. Breathing
frequency was monitored and not allowed to drop below 1 s−1, adjusting the
isoflurane levels accordingly at all times. Endpoint criteria and euthanasia.
Animal endpoint criteria encompassed weight loss of over 15%, restriction
of motor function by the engrafted tumor, dehydration of over 10%, and
moribund behavior. Where appropriate, the animals were euthanized by
asphyxiation in a CO2 chamber. Tumor tissue harvest. Animals were resected
and tumors excised using standard forceps, scissors, and surgical blades. The
tumors were combined into one sample per condition and mechanically
sheared in TRIzol, employing a specialized device (tissue tearer, model
985370). Total RNA workup was performed following the standard TRIzol
procedure, followed by a DNAse digest.
RNA-seq Sample Preparation and Data Processing. Double polyA-selection was
used in order to enrich for mRNA. RNA-seq libraries were prepared using
standard Illumina reagents and protocols (24) All experiments were carried
out in triplicate and 35 million–50 million single-end sequences of 50 bp were
generated for each library. One replicate was additionally sequenced as
100 bp paired-end reads for quality control purposes. Sequencing data were
mapped to a combined human and mouse transcriptome index (using the
hg19 and mm9 refSeq annotations) using Bowtie version 0.12.7 (25) with
two mismatches and an unlimited number of locations a read can map
to. Alignments were quantified on the transcript level using eXpress 1.0.0
(bio.math.berkeley.edu/eXpress/index.html); for each gene the quantifica-
tion values of all its transcripts were summed and the eXpress-determined
“effective counts” were used as input for differential expression analysis
using DESeq (16).
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